- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02949232
Prednisolone Addition for Patients With Recent-onset Psychotic Disorder
Prednisolone Addition for Patients With Recent-onset Psychotic Disorder: the Role of Immune-modulating Strategies in the Treatment of Psychosis
Study Overview
Status
Intervention / Treatment
Detailed Description
In the current study, the investigators aim to investigate the effect of additional treatment with prednisolone on symptomatic improvement, global functioning, cognition and on immunological parameters in patients with early-stage psychotic disorder, applying a randomized double-blind placebo-controlled add-on design. A placebo-controlled design was chosen in order to differentiate between clinical effects of prednisolone and effects associated with experimental treatment, such as induced expectations of participants. Prednisolone or placebo is provided next to existent antipsychotic medication as the investigators do not intend to replace existing treatment, this study being a Proof of Concept trial. It would carry considerable risks for patients to taper down existent antipsychotic medication and randomize patients to either placebo or a type of therapy for which the efficacy still has to be proven, even for a short period of time.
90 patients with schizophrenia, schizoaffective or schizophreniform disorder, or psychotic disorder NOS (not otherwise specified) will be included, with an age of 18-70 years and a time interval between the onset of psychosis and study entry not exceeding seven years. All 90 in- and outpatients will be randomized 1:1 to either prednisolone or placebo daily for 6 weeks. Prednisolone will be initiated at 40mg/day for 3 days and the 4 remaining days of the first week 30mg/dag will be used. During the treatment period, patients will be seen at weekly intervals to assess symptom severity, depressive mood and suicidal ideation, global functioning and side effects.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Antwerp, Belgium, 2060
- ZNA
-
-
-
-
-
Risskov, Denmark, 8240
- University Aarhus
-
-
-
-
-
Sliedrecht, Netherlands, 3361XV
- Yulius
-
Utrecht, Netherlands, 3508 GA
- UMC Utrecht
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A DSM-IV-R diagnosis of: 295.x (schizophrenia, schizophreniform disorder, or schizoaffective disorder) or 298.9 (psychosis NOS)
- Onset of psychosis no longer than 7 years ago
- Minimum total PANSS score of 60
- Age 18 -70 years
- Patients are treated with antipsychotic medication
- Written informed consent is obtained
- Female patients of childbearing potential need to utilize a proper method of contraception (the pill, vaginal ring, hormonal patch, intrauterine device, cervical cap, condom, contraceptive injection, diaphragm) in case of sexual intercourse during the study.
Exclusion Criteria:
- Presence of any of the contra-indications of prednisolone as reported in the SPC.
- Presence of diabetes mellitus or random (non-fasting) glucose levels exceeding 11 mmol/L at screening, severe heart failure, severe osteoporosis or systemic fungal infections.
- Body Mass Index (BMI) of >30.0
- Current or chronic use of systemic glucocorticosteroids (temporary use is permitted, if stopped 1 month before start of treatment trial)
- Chronic use of non-steroidal anti-inflammatory drugs, defined as daily use during more than 2 months. Intermittent use is permitted, if stopped at least 1 month before start of treatment trial.
- Pregnancy or breast-feeding. A urine pregnancy test will be performed at screening.
- Concurrent use of certain types of medication:
1. liver enzyme inducing medication such as carbamazepine, riphampicine, primidone, barbiturates and phenytoine
2. HAART medication (both HIV protease inhibitors and (non)-nucleoside reverse transcriptase inhibitors), especially efavirenz, ritonavir and lopinavir.
3. telaprevir and boceprevir in treatment of Hepatitis C
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prednisolone
Prednisolone will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following treatment guidelines for Inflammatory Bowel Diseases (2008).
|
prednisolone will be will be initiated during the first week at 40mg/day for 3 days and 30mg/day for 4 days, followed by a decrease of 5mg/day per week during the remaining 5 weeks; in the second week, patients will use 25 mg/day, in the third week 20 mg/day is used etc.
In the last week the patients will only take prednisolone on day 1-3 and day 5 and 7; a tapering scheme in line with the treatment guidelines for Inflammatory Bowel Diseases (2008).
|
Placebo Comparator: Placebo Oral Tablet
Placebo will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following the treatment schedule of the experimental arm
|
Dosing following the tapering scheme of the treatment of the treatment arm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in symptom severity
Time Frame: 6 weeks
|
Change in symptom severity is expressed as a change in total score on the Positive and Negative Symptom Scale (PANSS) from baseline to end of the 6-week treatment.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in cognitive functioning
Time Frame: 6 months
|
Cognitive functioning is measured through the Brief Assessment of Cognition in Schizophrenia (BACS).
|
6 months
|
Change in GAF scores
Time Frame: 1 year
|
Global Assessment of Functioning
|
1 year
|
Measurement of various immunological biomarkers
Time Frame: 6 months
|
Cytokine panels will be analysed
|
6 months
|
Improvement of PANSS scores in follow-up
Time Frame: 1 year
|
PANSS follow-up; 4 months, 6 months and 12 months
|
1 year
|
Score on the Calgary Depression Scale for Schizophrenia (CDSS)
Time Frame: 6 weeks
|
CDSS scores will be analysed
|
6 weeks
|
Incidences of key SAEs and SUSARs
Time Frame: 1 year
|
Safety analyses
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Iris Sommer, Prof. Dr., UMC Utrecht
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Disease
- Psychotic Disorders
- Mental Disorders
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Prednisolone
Other Study ID Numbers
- NL46653
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Rakitzi, StavroulaActive, not recruiting
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on Prednisolone
-
Children's Hospital of PhiladelphiaCompleted
-
Assiut UniversityCompleted
-
Hamamatsu UniversityCompletedChronic Disease | Eosinophilic PneumoniaJapan
-
Sparrow PharmaceuticalsRecruitingPolymyalgia RheumaticaGermany
-
IsalaCompletedChronic Obstructive Pulmonary DiseaseNetherlands
-
Institute of Child HealthUnknown
-
Postgraduate Institute of Medical Education and...Completed
-
Postgraduate Institute of Medical Education and...CompletedPost COVID-19 Diffuse Lung DiseaseIndia
-
Nanjing University School of MedicineCompleted
-
Cambridge University Hospitals NHS Foundation TrustUniversity Medical Center Groningen; Imperial College London; University Hospitals... and other collaboratorsTerminatedWegener's Granulomatosis | Microscopic PolyangiitisUnited Kingdom